Adam Knott
- Oncology top 0.5%
- HER2/EGFR in Cancer Research 24
- Peptidase Inhibition and Analysis 9
- Cancer Treatment and Pharmacology 8
- Cancer Research top 2%
- Breast Cancer Treatment Studies 9
-
- Monoclonal and Polyclonal Antibodies Research 7
-
- Cardiomyopathy and Myosin Studies 8
- Cardiovascular Effects of Exercise 5
-
- Muscle Physiology and Disorders 5
Adam Knott
31 papers receiving 4.1k citations
Hit Papers
Peers
Comparison fields: 5 of 95
- Oncology 3.2k
- Cancer Research 1.0k
- Radiology, Nuclear Medicine and Imaging 1.4k
- Pulmonary and Respiratory Medicine 984
- Cardiology and Cardiovascular Medicine 615
Countries citing papers authored by Adam Knott
This map shows the geographic impact of Adam Knott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Knott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Knott more than expected).
Fields of papers citing papers by Adam Knott
This network shows the impact of papers produced by Adam Knott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Knott. The network helps show where Adam Knott may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Adam Knott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 22 | |
| 3 | 2023 | 0 | |
| 4 | 2022 | 15 | |
| 5 | 2022 | 18 | |
| 6 | 2019 | 9 | |
| 7 | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancerbreakdown → | 2017 | 918 |
| 8 | 2017 | 0 | |
| 9 | 2014 | 48 | |
| 10 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studybreakdown → | 2013 | 700 |
| 11 | 2013 | 43 | |
| 12 | 2013 | 106 | |
| 13 | 2013 | 19 | |
| 14 | 2013 | 2 | |
| 15 | Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancerbreakdown → | 2011 | 1773 |
| 16 | 2002 | 31 | |
| 17 | 2002 | 35 | |
| 18 | 2002 | 109 | |
| 19 | 2002 | 23 | |
| 20 | 2000 | 60 |
About Adam Knott
Adam Knott is a scholar working on Oncology, Cancer Research, Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging and Developmental Neuroscience, having authored 33 papers that have together received 4.2k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (24 papers), Peptidase Inhibition and Analysis (9 papers), Breast Cancer Treatment Studies (9 papers), Cardiomyopathy and Myosin Studies (8 papers), Cancer Treatment and Pharmacology (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Muscle Physiology and Disorders (5 papers) and Cardiovascular Effects of Exercise (5 papers). The work is most often cited by research in Oncology (3.2k citations), Cancer Research (1.0k citations), Radiology, Nuclear Medicine and Imaging (1.4k citations), Pulmonary and Respiratory Medicine (984 citations) and Cardiology and Cardiovascular Medicine (615 citations). Adam Knott has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Emma Clark, Mark Benyunes, Sandra M. Swain, Graham Ross, Javier Cortés, José Baselga, Sung‐Bae Kim, Young‐Hyuck Im, Seock‐Ah Im and Tadeusz Pieńkowski. Their work appears in journals such as Journal of Clinical Oncology, Biochemical Journal, Cancer Research, Journal of Molecular and Cellular Cardiology and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.